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ABSTRACT A critical appraisal and clinical application 
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Clinical Context 
A six-year-old asthmatic child presented to the clinic after an emergency room visit for an acute asthma 
exacerbation.  Upon further questioning, it was disclosed that prior to the emergency room visit, the child both 
required albuterol treatments more than twice weekly and had interrupting nighttime symptoms that occurred 
more than once per month.  Based on this presentation, the patient was categorized as an uncontrolled persistent 
asthmatic and, according to standard clinical gu
therapy. 
Clinical Question 
What is the effect of inhaled glucocorticoids during childhood on adult height?
Research Article 
Kelly HW, Sternberg AL, Lescher R, et al. Effect of inhaled glucoc
367(10):904-912. doi:10.1056/NEJMoa1203229
Literature Review 
Multiple studies have shown that there is a clear reduction in growth velocity in
prepubertal initiation of an inhaled glucocorticoid.




A small prospective study done in 1996 (N=332) was of limited value because there were 59 participants lost to follow
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 However, the majority of studies that have been done to evaluate a permanent 
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In a case-controlled study done in 1996 (N=306), which was controlled for mid
was no permanent impact on achievement of adult height. The study depended on poorly described methods of chart review to 
identify subjects, which limited its validity.  
A meta-analysis of 95 articles done in 1994 compared attained heights to expected heights in patients exposed to steroids. The 
authors concluded that there was a small but significant tendency of corticosteroid therapy to be associated with diminished 
height, but that overall, inhaled use of corticosteroids did not significantly impact stature.
Critical Appraisal 
The Childhood Asthma Management Program trial is designed to determine the benefits of an inhaled corticosteroid in persisten
asthmatics.
4
 The article under review, written b
CAMP Trial data. Kelley, et al. compare height differences between asthmatics treated with inhaled budesonide, inhaled nedocr
or placebo. After the first four-to-six years, the participants were followed into adulthood to measure their attained heights. During 
the first four-to-six years, protocol adherence was good: 636.1 mg glucocorticoid dose in the budesonide group, 88.5 mg in the 
nedocoromil group, and 109.4 mg in the placebo group. At that time, researchers reported a significant difference in participants
heights that persisted into adulthood. They also reported a difference between the inhaled corticosteroid group and the place
group: 1.2 cm shorter 95% CI [−1.9 to −0.5 cm], (
the three groups: 381 mg, 347 mg, and 355 mg, respectively. Therefore, the authors
adult height is not supported. 
This randomized trial, which includes the important outcome variable of adult height, is relevant because clinicians frequent
encounter patients such as those enrolled in the study and are called upon to advise parents regarding the risk of harm
benefit for inhaled glucocorticoids in asthmatic children. During the study, follow
according to the group into which they were randomized. Because the inhalation devices may have been distinguishable to 
participants, the study lacked strong blinding protocols. Otherwise, the groups were treated equally. The limitations of the 
include the investigation of a single agent, budesonide, without consideration of any other corticosteroids, and administ
single dose, 200 ug twice daily, instead of the now recommended dose of 200 ug once daily.  The study may have yielded more 
useful clinical applications had the authors administered a lower dose of budesonide or included alternative corticoster
 
Clinical Application 
In the clinic, the primary care team explained to the parents that daily inhaled corticosteroid use may cause a 
reduction in adult height, about 1 cm or more, with continued use.  The parents were dismissive of this 
information; they thought the benefit of keeping their child out of the hospital and controlling the asthma 
episodes were far greater concerns than was a small height loss.
The primary care team learned that despite the seemingly authoritative claims of Kelley, et al.
uncertainty about the effects of inhaled glucocorticoid therapy in an asthmatic child with regard to his/her adult 
height. For the care of future, similar patients, we believe shared decision
should include a discussion of the potential impact of continued glucocorticoid use on a child
Socially and culturally speaking, height is considered a desirable physical trait; while 1 cm of height loss may seem 
trivial to one person, it may be an unacceptable consequence to another.  If the parent or the child has a shorter 
stature and does not want to risk further height deficiencies, this information might impact therapeutic choices.
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